Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Glycogen synthase kinase 3 (GSK3) remains a therapeutic target of interest for diverse clinical indications. However, one hurdle in the development of small molecule GSK3 inhibitors has been safety concerns related to pan-inhibition of both GSK3 paralogs, leading to activation of the Wnt/β-catenin pathway and potential for aberrant cell proliferation. Development of GSK3α or GSK3β paralog-selective inhibitors that could offer an improved safety profile has been reported but further advancement has been hampered by the lack of structural information for GSK3α. Here we report for the first time the crystal structure for GSK3α, both in apo form and bound to a paralog-selective inhibitor. Taking advantage of this new structural information, we describe the design and in vitro testing of novel compounds with up to ∼37-fold selectivity for GSK3α over GSK3β with favorable drug-like properties. Furthermore, using chemoproteomics, we confirm that acute inhibition of GSK3α can lower tau phosphorylation at disease-relevant sites in vivo, with a high degree of selectivity over GSK3β and other kinases. Altogether, our studies advance prior efforts to develop GSK3 inhibitors by describing GSK3α structure and novel GSK3α inhibitors with improved selectivity, potency, and activity in disease-relevant systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GSK-3α ATP-competitive inhibitor 35 could cross the BBB and significantly reduce tau phosphorylation at pThr231 in neonatal rat brains”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [497]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As the role of GSK-3α in promoting Aβ production and tau phosphorylation in AD models is recognized”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [497]
The cited source says what the claim attributes to it.
In the citing paper
“selective inhibition of GSK-3α has emerged as a promising therapeutic strategy.494,496,497”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [497]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Functional Interaction of an Axin Homolog, Conductin, with β-Catenin, APC, and GSK3β
Behrens, J., Jerchow, B.-A., Würtele, M., Grimm, J., Asbrand, C., Wirtz, R., Kühl, M., Wedlich, D., & Birchmeier, W. (1998) · Science · doi:10.1126/science.280.5363.596 · Cited by 1,260
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897
Crystal Structure of Glycogen Synthase Kinase 3β
Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., & Pearl, L. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00374-9 · Cited by 674
Research works printed but not linked: 1
- Miyoshi Y., 1998, Cancer Res., 58, 2524
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
GSK3: A potential target and pending issues for treatment of Alzheimer's disease
Zhao, J., Wei, M., Guo, M., Wang, M., Niu, H., Xu, T., & Zhou, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14818 · Cited by 295
Khan, Z. R., Welsby, P. J., Stasik, I., & Hayes, J. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00373 · Cited by 12
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 11
Valero-Rojas, J., Ramírez-Sánchez, C. A., Pacheco-Paternina, L., Valenzuela-Hormazábal, P., Saldívar‐González, F. I., Santana, P., González, J., Gutiérrez-Bunster, T., Valdés-Jiménez, A., & Ramírez, D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01481 · Cited by 8
Jing, H., Richardson, P. L., Potts, G. K., Senaweera, S., Marin, V. L., McClure, R. A., Banlasan, A., Tang, H., Kath, J. E., Patel, S., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00696 · Cited by 4
Role of GSK-3 Inhibition in Alzheimer’s Disease Therapy
Algazzawi, H., Abujamai, J. Z., Alshanberi, A. M., Satar, R., & Ansari, S. A. (2025) · Current Alzheimer Research · doi:10.2174/0115672050400781250904082943 · Cited by 3
Machine Learning Prediction and Simulation of Drugs Targeting GSK-3β in Breast Cancer
Munieswaran, G., Subramani, N. K., & Venugopal, S. (2024) · Current Drug Therapy · doi:10.2174/0115748855333541240819111638 · Cited by 3
Emmerich, T. D., Taylor-Chilton, E. J., Caballero, E., Hushcha, I., Dickens, K., Stasik, I., Alder, J. E., Saavedra-Castano, S., Berenschot, E., Tas, N. R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00377 · Cited by 3
Díaz-Sánchez, F., Arzola-Flores, J. A., Cárdenas-García, M., García‐Castro, M. A., & Santamaría‐Juárez, J. D. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c01172 · Cited by 3
GSK3A promotes human adenovirus replication and phosphorylates viral L4-22K protein
Lin, Y., Zhu, Y., Jing, L., Chen, Y., Xiao, X., Lei, X., & Xie, Z. (2025) · Life Science Alliance · doi:10.26508/lsa.202503320 · Cited by 2
“Subsequently, a protein – protein docking analysis was performed on the ClusPro 2.0 platform to visualize the binding pattern between GSK3A (PDB: 7SXF) and L4-22K (Jones et al, 2022; Amaral et al, 2023).”
InfluentialValenzuela-Hormazábal, P., Valero-Rojas, J., Martínez‐González, L., Ramos-Inza, S., Oviedo-Pino, V., González-Ortega, C., Hernando, G., López, J. J., Scorza, C., Echeverry, C., et al. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02202 · Cited by 2
Thyagarajan, S., Subramanian, K., Rasul, H. O., Mohammed, O. S., Salgado‐Morán, G., & Candia, L. G. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152675 · Cited by 1
Developments in the design and therapeutic applications of GSK3β inhibitors
Daoud, S., & Taha, M. O. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2675873 · Cited by 1
Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine
Schiroli, D., Merra, A., Marraccini, C., Merolle, L., Pellegrini, G., & Maurizi, E. (2026) · Medicinal Research Reviews · doi:10.1002/med.70095 · Cited by 1
Conception, synthèse et analyse structurales de composés hétéroaromatiques à visée thérapeutique
Hasyeoui, M. (2023) · theses.fr (ABES) · doi:10.70675/30bd27c6z7227z4020zbbdazbcf2651568ce
Trivedi, S. J., Roy, S. M., & Roy, D. R. (2026) · Interactions · doi:10.1007/s10751-026-02575-x
“The GSK-3β phosphorylation is co-articulated by the Aβ peptides aggregation [7, 8].”
Synthesis and in vitro/in silico evaluation of AuNP–DITA systems against breast cancer cell lines
Cárdenas-García, M., Díaz-Sánchez, F., García‐Castro, M. A., Arzola-Flores, J. A., & Santamaría‐Juárez, J. D. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103453
Deep learning–assisted virtual screening of a large chemical library for selective GSK3β inhibitors
Varma, T., Kamble, P., & Garg, P. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11697-x
Khamamkar, A., Roy, R., S, D. A., Choudhari, N., Dutta, R., Weïwer, M., Adiga, S. K., Vijayaraghavan, S., & Dey, S. (2026) · Molecular Human Reproduction · doi:10.1093/molehr/gaag049
Paralog-specific roles of GSK-3 in synaptic plasticity and behaviour in the adult mouse hippocampus
Kang, S. (2026) · TSpace (University of Toronto)
Chen, H., Zhang, L., Jiao, B., Sun, X., Guan, L., Niu, R., Li, B., Jiang, X., & Wu, Z. (2026) · Pharmaceuticals · doi:10.3390/ph19091457
Cui, H., Li, H., Wang, W., Li, J., Cai, M., Wang, Y., Zhang, Y., & Li, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118475
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Metadata
- Authors
- Amaral, B., Capacci, A., Anderson, T., Tezer, C., Bajrami, B., Lulla, M., Lucas, B., Chodaparambil, J. V., Marcotte, D., Kumar, P. R., Murugan, P., Spilker, K., Cullivan, M., Wang, T., Peterson, A. C., Enyedy, I., Ma, B., Chen, T., Yousaf, Z., Calhoun, M., Golonzhka, O., Dillon, G. M., & Koirala, S.
- Affiliations
- Biogen (United States) (US)
- Corresponding author
- Capacci, Andrew
- ORCID
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-02-22
- Volume
- 14
- Issue
- 6
- Pages
- 1080-1094
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC10020971
- OpenAlex
- W4321488198
- Cited by
- 22
- References
- 59
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 5
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- glycogen synthase kinase-3, GSK3α, GSK3β, crystal structure, kinase inhibitor design, Wnt/β-catenin signaling, tau phosphorylation, chemoproteomics, Alzheimer's disease, kinase selectivity
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Phosphorylation, Protein Serine-Threonine Kinases, Glycogen Synthase Kinase 3, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.